Circadian Disturbances After Breast Cancer Surgery

NCT ID: NCT01171508

Last Updated: 2013-03-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

12 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-02-28

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate circadian disturbances after breast cancer surgery by means of monitoring sleep and heart-rate variability, by measuring a metabolite of melatonin in urine and by questionnaires and a sleep-diary.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An increasing number of studies have shown that circadian variation in the excretion of hormones, the sleep-wake cycle, the core body temperature, the tone of the autonomic nervous system and the activity rhythm are important both in health and disease processes. More attention is being paid towards the circadian variation in endogenous rhythms in relation to surgery and whether this can affect postoperative recovery, morbidity and mortality.

Studies have been done on circadian disturbances after major and minor surgery but never in relation to breast cancer surgery.

This study will investigate circadian disturbances in this specific group of patients by using Actigraphy, Polysomnography (PSG), Holter-monitoring (HRV), the primary metabolite of melatonin in urine 6-sulfatoxymelatonin (aMT6s), questionnaires and a sleep-diary.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Circadian Rhythm Disorders Anxiety Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast cancer patients

12 breast cancer patients aged 30-70 years undergoing a lumpectomy at Herlev Hospital. ASA score I-III.

Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA

Intervention Type DEVICE

Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.

Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)

Intervention Type DEVICE

Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).

Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)

Intervention Type DEVICE

Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.

Urine 6-sulphatoxymelatonin (aMT6s)

Intervention Type PROCEDURE

Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.

Karolinska Sleepiness Scale

Intervention Type OTHER

Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.

Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain

Intervention Type OTHER

Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.

Sleep-diary

Intervention Type OTHER

Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA

Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.

Intervention Type DEVICE

Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)

Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).

Intervention Type DEVICE

Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)

Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.

Intervention Type DEVICE

Urine 6-sulphatoxymelatonin (aMT6s)

Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.

Intervention Type PROCEDURE

Karolinska Sleepiness Scale

Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.

Intervention Type OTHER

Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain

Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.

Intervention Type OTHER

Sleep-diary

Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women, age 30-70, with breast cancer who are admitted for a lumpectomy at Herlev Hospital
* ASA score I-III

Exclusion Criteria

* Known sleep apnea
* Pre-operative treatment with beta-blockers
* Diabetes Mellitus
* Known pre-operative depressive illness or dementia
* Previous or current cancer
* Known medically treated sleep-disorder (insomnia, restless legs etc)
* Shift-work
* Daily alcohol intake of more than 5 units
* Pre-operative treatment with psychopharmacological drugs, opioids or anxiolytics (including all sleeping pills)
* Predicted bad compliance
* Pregnant or breast-feeding
* Pre- or post-operative complications or events which are expected to increase morbidity or pain the first post-operative days.
* Missing written consent
* Pre-operative MMSE score less than 24
* Urine or fecal incontinence
Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Melissa Voigt Hansen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Melissa Voigt Hansen

M.D. ph.D student

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Melissa V Hansen, MD

Role: PRINCIPAL_INVESTIGATOR

Herlev Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Herlev Hospital

Copenhagen, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MVH-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Melatonin and Cardiac Outcome After Major Surgery
NCT00315926 COMPLETED PHASE2/PHASE3